Fuse Oncology, a structured AI platform for radiation oncology, announced on Monday the launch of FuseRx, a prescribing and treatment-intent solution for radiation oncology.

According to Fuse Oncology, FuseRx is the keystone of the Fuse platform, connecting the consult to simulation, planning, and treatment. Physicians create a complete, structured treatment intent -- simulation orders, prescriptions, target and organ-at-risk goals, and supporting orders -- in a single guided workflow. Clinic-configurable templates, a built-in validation engine with configurable safety checks and hard stops, and a full change-request audit trail replace fragmented, paper-and-PDF prescribing processes that slow the start of care.

The company says that FuseRx is built to support clinical pathways at the point of prescribing -- whether institution-specific protocols or published evidence-based guidelines. Building on the strategic agreement announced in March 2025, ACRO's ACROPath pathways will be among the first to integrate directly into the FuseRx workflow, giving clinicians guideline-concordant decision support at the moment treatment decisions are made -- reducing care variation while preserving physician judgement.

FuseRx joins S!GNAL and FuseDocs on Fuse's unified platform, sharing one patient context, one worklist model, and structured data captured from the consult forward.